Chronic pulmonary hypertension is associated with extensive structural remodeling of the pulmonary arterial bed. The structural changes in the arterial walls include increased production of extrace~lular matrix components and smooth muscle cell hypertrophy, changes that have been similarly induced by transforming growth factor-f, (TGF-ft) in culture. In the present study, experiments were performed to determine whether TGF-ft is present in sheep lung lymph, and whether TGF-fi levels were altered in an animal model of chronic pulmonary hypertension induced by continuous air embolization. Several standard biological assays for TGF-fl activity were used for these determinations including soft agar assays, inhibition of epithelial cell proliferation, and a TGF-,8-specific radiorecep- 
Introduction
Transforming growth factor-# (TGF-f3)' was originally defined by its ability to transform fibroblasts in culture (1, 2) , however, numerous and diverse biological effects have now been reported (3) . For example, TGF-f3 stimulates the production of extracellular matrix components and protease inhibitors but decreases the production of proteases such that the overall effect is an increase in synthesis and deposition of extracellular matrix components (4) (5) (6) (7) (8) . TGF-,3 also stimulates elastin pro-murine keratinocytes; TGF-f3, transforming growth factor-,#. duction in cultured vascular smooth muscle cells (9) , hypertrophy of smooth muscle cells (10) , and depending on the culture conditions, smooth muscle cell proliferation can be stimulated or inhibited (1 1).
TGF-/3 has been found to be ubiquitous; it has been detected in a variety of cultured cells, normal and neoplastic tissues (12) , and serum (13). Platelets are one of the richest sources of TGF-,B (14) . TGF-,B is released from cells and platelets in a latent, biologically inactive form that can be activated by extremes of pH (15) , although a more physiological mechanism ofactivation has been proposed to involve proteases (16) . It is likely that activation of latent TGF-,B plays an important role in the regulation of its action.
Chronic pulmonary hypertension often occurs as a secondary complication of many pulmonary disorders such as bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema. In some cases the hypertension becomes the predominant problem leading to death. Currently no therapy is available for the reversal of severe chronic pulmonary hypertension with the exception of heart or lung transplant. The irreversible disease is thought to result from extensive structural remodeling of the pulmonary arteries. Pathological evaluation of lung tissue from both human disease and animal models has defined a spectrum of characteristic changes that occur in the pulmonary arterial circulation. These changes include increased medial and adventitial thickness, appearance of muscle in normally nonmuscular arterial walls, and reduction in peripheral arterial volume (17). Since increased production of extracellular matrix and smooth muscle hypertrophy are features of the wall of hypertensive pulmonary arteries, and TGF-,f has been shown to induce similar changes in vitro, it is possible that TGF-p contributes to the development of this disease.
TGF-fl has been shown to be present in human lung lavage fluid (18) , but this fluid may not be representative of findings in lung interstitium and vascular walls. In sheep, interstitial fluid can be collected as it exits the lung from the caudal mediastinal lymph node. Biochemical markers oflung damage such as increased protein flux (19) , increased prostanoid release (20) , and free radical production (21) have been successfully measured in lung lymph. TGF-fl has not been measured in lung lymph.
This study uses control sheep to examine whether TGF-fl can be detected in lung lymph. The study also uses a model of chronic pulmonary hypertension in which sheep receive continuous air embolization (22) to assess whether levels of TGF-,B are altered during the development ofthis disease. The data indicate that latent TGF-,B is a normal constituent of lung lymph and that its levels increase early during the onset of pulmonary hypertension. TGF-,B may be linked to the development of the structural changes of chronic pulmonary hypertension. Soft agar assay. Lung lymph was evaluated for its ability to stimulate the growth of AKR-2B (clone 84A) cells in soft agar using previously described methods (1, 13 Radioreceptor assayfor TGF-f3
A competitive radioreceptor assay was used to detect and quantitate TGF-j3 in lung lymph from control and air embolized animals. This assay is specific and not influenced by the presence of other growth factors present in lung lymph. Lung lymph samples were diluted 10-fold with binding buffer (128 mM NaCl, 5 mM KCI, 5 mM MgSO4, 1.2 mM CaCl2, 50 mM Hepes, 2 mg/ml bovine serum albumin). Latent TGF-,# was activated in an aliquot from each sample by transient acidification. The receptor assay was performed essentially as previously described (27, 28 A standard curve was constructed using porcine platelet-derived TGF-f3 and showed that 1 ng/ml of TGF-,B resulted in 50% inhibition.
The concentration of TGF-4 in lung lymph was calculated by assuming that the volume of lymph resulting in 50% inhibition contained 1 ng of TGF-#.
Results

Control lung lymph
Soft agar assay. Sheep lung lymph stimulated fibroblast colony formation in soft agar (Fig. 1 Radioreceptor assay. Acid-activated lung lymph from control sheep competed strongly for binding in the radioreceptor assay (Fig. 3 A) . Approximately 10 Ml oflymph resulted in 50% inhibition of '25I-TGF-# binding (Fig. 3 A) . The results were remarkably similar in all control samples tested and similar results were obtained with samples taken from the same animal more than 1 wk apart. No activity could be detected in an untreated lung lymph sample that was assayed immediately after collection (data not shown). Some samples that were frozen before assay showed small but detectable amounts ofactivity, perhaps reflecting activation of TGF-,3 during storage.
Since most samples were frozen before the assays, it was not possible to determine whether any TGF-# was active in control lung lymph. Freezing and storage did not alter the amount of total activity detected in acid-treated samples.
As can be seen in Fig. 3 TGF-D (ng/ml) resulted in 50% inhibition of the binding of '25I-TGF-f.l. Thus the calculated concentration of TGF-# in acid-treated control lung lymph was -100 ng/ml.
"Hypertensive" lung lymph Radioreceptor assay. Acid-treated lung lymph collected from sheep during air embolization showed an increase in TGF-, competing activity over control lung lymph (Fig. 4) . The concentrations of TGF-# in lung lymph at baseline and during air embolization are shown (Fig. 4 A) TGF-t? flux during the first days of embolization which returned to control values by day 7 (Fig. 4 B) .
Discussion
Little is known of the role of TGF-3 in vivo either under normal or pathological conditions. This study demonstrates that TGF-ft is a normal constituent of sheep lung lymph and that the levels increase transiently before the development of pulmonary hypertension.
The cellular origin of TGF-4 in lung lymph is not known. Lung lymph is a filtrate of plasma, with the addition of factors present or produced in the interstitium and vessel walls. Normal plasma does not contain TGF-3 (13), however it is possible that circulating platelets or inflammatory cells release TGF-3. A recent study of human epithelial lining fluid has suggested that airway cells, particularly alveolar macrophages, are the source of TGF-# detected in normal human epithelial lining fluid (18, 29) . While it is possible that the airway cells contribute to the level of TGF-# in lung lymph, the level is tenfold greater than that found in epithelial lining fluid, suggesting that TGF-# is also produced by other cells in the interstitium and/or vascular wall. Endothelial cells (30) and lymphocytes (31, 32) have been reported to produce TGF-# in vitro and may also contribute to the TGF-4 in lung lymph.
Platelets are a rich source of TGF-# (13, 14) but they are not present in lung lymph.
The level of TGF-# in sheep lung lymph is higher (100 ng/ml) than that required for a maximal response in a variety of in vitro biological assays (-10 ng/ml). It This study has shown an increase in lung lymph TGF-f3 during air embolization before the onset of sustained pulmonary hypertension. In this model, the pulmonary hypertension is accompanied by several well characterized structural changes in the pulmonary arterial bed including an increase in medial thickness secondary to matrix deposition, smooth muscle hypertrophy, and perhaps hyperplasia (22) . Signifi (38) . Similarly, TGF-,3 stimulates c-sis (B chain of platelet-derived growth factor) in human endothelial cells (39) . Platelet-derived growth factor is not only a potent smooth muscle cell mitogen (40) , but also a vasoconstrictor (41 In summary, we have shown that sheep lung lymph contains high levels of TGF-f, activity. This activity increases during continuous air embolization before the development of structural remodeling ofthe pulmonary arteries. The data suggest that TGF-,B could be involved in the response of the lung to the vascular changes induced by air embolization. Further studies are needed to identify the source ofTGF-fl and mechanisms for its activation.
